IO Biotech, Inc. financial data

Symbol
IOBT on Nasdaq
Industry
Pharmaceutical Preparations
Location
Ole Maaloes Veh 3, Copenhagen, Denmark
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 31, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 635 % -43.5%
Debt-to-equity 19.9 % +77.8%
Return On Equity -115 % -73.9%
Return On Assets -96.2 % -61.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 65.9M shares 0%
Common Stock, Shares, Outstanding 65.9M shares 0%
Entity Public Float 60.6M USD +94.9%
Common Stock, Value, Issued 66K USD 0%
Weighted Average Number of Shares Outstanding, Basic 65.9M shares +51.3%
Weighted Average Number of Shares Outstanding, Diluted 65.9M shares +51.3%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 71.5M USD +5.39%
General and Administrative Expense 23.7M USD +0.34%
Operating Income (Loss) -95.2M USD -4.08%
Nonoperating Income (Expense) 1.13M USD -81.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -94M USD -10.3%
Income Tax Expense (Benefit) 1.44M USD +69.4%
Net Income (Loss) Attributable to Parent -95.5M USD -10.9%
Earnings Per Share, Basic -1.45 USD/shares +26.8%
Earnings Per Share, Diluted -1.45 USD/shares +26.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 60M USD -58.1%
Assets, Current 65M USD -55.9%
Property, Plant and Equipment, Net 638K USD -24.7%
Operating Lease, Right-of-Use Asset 1.73M USD -23.6%
Other Assets, Noncurrent 117K USD +31.5%
Assets 67.7M USD -55.1%
Accounts Payable, Current 4.66M USD +20.2%
Employee-related Liabilities, Current 4.31M USD +2.04%
Liabilities, Current 19.5M USD +24%
Operating Lease, Liability, Noncurrent 1.2M USD -34.9%
Liabilities 20.7M USD +17.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax -6.85M USD +29.1%
Retained Earnings (Accumulated Deficit) -359M USD -36.2%
Stockholders' Equity Attributable to Parent 47M USD -64.7%
Liabilities and Equity 67.7M USD -55.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -24.9M USD -69.7%
Net Cash Provided by (Used in) Investing Activities -11K USD +92.6%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 65.9M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Deferred Tax Assets, Valuation Allowance 77.2M USD +33.2%
Deferred Tax Assets, Gross 77.6M USD +32.9%
Depreciation 62K USD +31.9%
Payments to Acquire Property, Plant, and Equipment 11K USD -92.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -92.7M USD -8.25%
Lessee, Operating Lease, Liability, to be Paid 2.08M USD -25.3%
Operating Lease, Liability, Current 717K USD +9.47%
Lessee, Operating Lease, Liability, to be Paid, Year Two 829K USD +4.67%
Lessee, Operating Lease, Liability, to be Paid, Year One 819K USD +3.28%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, to be Paid, Year Three 434K USD -45.6%
Deferred Tax Assets, Operating Loss Carryforwards 66.7M USD +32.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 0 USD -100%
Operating Lease, Payments 193K USD +10.3%
Additional Paid in Capital 413M USD +1.61%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 300K USD +50%
Deferred Tax Assets, Net of Valuation Allowance 415K USD -13.4%
Share-based Payment Arrangement, Expense 6.53M USD -19%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%